The Asabys-Aliath integration signals how European biotech VCs are scaling and adapting amid funding pressures.
Discover the top biotech deals of September 2025, as four billion-dollar acquisitions took place and several licensing deals ...
Discover how AKIGAI’s EGFR inhibitors may redefine neuropathic pain therapy and offer hope for complex regional pain syndrome ...
Qure, Dianthus Therapeutics, and Mineralys Therapeutics bagged the biggest biotech funding rounds overall in September 2025.
The U.K. has had a stronghold on the biopharma and healthcare industry for a long time and remains one of the top hubs for ...
Asthma affects around 260 million people worldwide, making it one of the most common chronic respiratory conditions. Despite advances in treatment, it still contributes to hundreds of thousands of ...
Explore what FDA approval of elamipretide means for ultra-rare disease drug development and the outlook for future biotech ...
BIOSPAIN 2025 returns to Barcelona, bringing 2,200+ biotech professionals for networking, collaborations, and industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback